Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
about
Science review: The use of proton pump inhibitors for gastric acid suppression in critical illnessPharmacokinetic drug interaction profiles of proton pump inhibitors: an updatePantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleedingInteraction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sourcesPantoprazole-induced thrombocytopenia in patients with upper gastrointestinal bleeding.Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in KoreaAn update on the use of pantoprazole as a treatment for gastroesophageal reflux diseaseRole of pantoprazole in the treatment of gastro-oesophageal reflux disease.CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteersInhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover studyLong-term management of GERD in the elderly with pantoprazole.Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products.Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patientsReview of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.Impairment of salivary mucin production resulting in declined salivary viscosity during naproxen administration as a potential link to upper alimentary tract mucosal injury.Acute interstitial nephritis due to pantoprazole.Agglomerates containing pantoprazole microparticles: modulating the drug release.Long-term management of gastroesophageal reflux disease with pantoprazole.Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease.Synthesis of difluoromethyl ethers with difluoromethyltriflate.Inappropriate utilization of intravenous proton pump inhibitors in hospital practice--a prospective study of the extent of the problem and predictive factors.Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years.Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR.Improvement of Non-Steroidal Anti-Inflammatory Drug-Induced Gastrointestinal Symptoms during Proton Pump Inhibitor Treatment: Are G-Protein β3 Subunit Genotype, Helicobacter pylori Status, and Environmental Factors Response Modifiers?
P2860
Q24802292-DBF9508B-D00B-48EC-AD36-7B7830B8C89BQ27022254-4B2F379D-7EC3-4693-8D15-C85AC4C2C9EFQ27025841-169D2839-CAB4-4FC1-A135-9172675857F9Q28250490-2BE6E59E-EC12-4164-9A51-DFED33C36276Q33413259-839C0C3C-39F5-4224-8809-4BB35313B1CFQ33853179-B3AA8827-358B-435B-88D9-C89BD8053A8FQ34194502-2DAE150D-3F7F-4A79-8353-E55E6C647F45Q36040702-C6828905-E212-4CDA-B2E5-2EB582293F40Q36164941-8A657290-91F2-4681-A43F-2F6B54CDB5ABQ36576842-8F52C547-78C9-4954-9637-751EE32EF936Q37017283-8C5EECE5-3A53-4DFD-9566-7B9B7DEC2552Q37098768-B040B817-7584-4C0C-AF52-1E9F089F2B27Q37161518-FF99D9FC-360E-410A-AE96-A8EEE3EF3BE5Q38237417-21F7AB89-0AB9-418F-AF8E-7406D0B9F8EFQ39261341-D2F0D4CB-6210-4254-9394-7E8C4DC90465Q40126599-DD24AC64-91FB-4454-BE0F-738851E4B95DQ40541481-82143851-DA53-4CDF-9791-178C3DC13926Q41989306-D6B5B506-8B3A-44AD-849E-896940A8F1B9Q42429093-39F9C0AE-A744-41E7-9F97-9E02356DAA4AQ42645500-DB93A8E9-5298-49F2-8CAE-C94C8A0F53CBQ42905296-01BAE46E-DECE-4A86-A187-D6A7CCB935F7Q43138290-B8E90FC8-84DD-4524-BC9E-0C1733E7B82BQ46322531-71A60206-5E78-4D47-B303-0EACFC06649CQ46559957-FFD755E6-C06C-4C2B-A1BF-59A2B0BFD9B6Q51461774-C697C2D9-A830-4F1F-AB0D-356E576B8356Q53830142-43D83248-C040-44AB-9606-6675A61E80C7Q57789427-6B93F706-1624-4EA5-80B5-224993A6FEC0
P2860
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pantoprazole: an update of its ...... ent of acid-related disorders.
@ast
Pantoprazole: an update of its ...... ent of acid-related disorders.
@en
type
label
Pantoprazole: an update of its ...... ent of acid-related disorders.
@ast
Pantoprazole: an update of its ...... ent of acid-related disorders.
@en
prefLabel
Pantoprazole: an update of its ...... ent of acid-related disorders.
@ast
Pantoprazole: an update of its ...... ent of acid-related disorders.
@en
P2093
P1433
P1476
Pantoprazole: an update of its ...... ent of acid-related disorders.
@en
P2093
Amitabh Prakash
Diana Faulds
Harriet M Lamb
Susan M Cheer
P304
P356
10.2165/00003495-200363010-00006
P577
2003-01-01T00:00:00Z
P6179
1019222132